Everything below concerns Dual agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
| Property | Value | Notes |
|---|---|---|
| Molar mass | approximately 4813 Da | calculated from the 39-residue sequence |
| Appearance | white to off-white powder | typical of lyophilised peptide material |
| Solubility class | freely soluble in water | measured value depends on salt form and pH |
| Plasma protein binding | >99 percent | linked to the fatty diacid side chain |
| Class | dual GIP and GLP-1 receptor agonist | receptor activity varies with the assay used |
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Propofol is the active component of an intravenous anesthetic used for induction and maintenance of general anesthesia. Propofol was first marketed under the brand name Diprivan. Intravenous administration is used to induce unconsciousness, after which anesthesia may be maintained using a combination of medications. Propofol is manufactured as part of a sterile injectable emulsion using soybean oil and lecithin, which gives it a white milky color. Compared to other anesthetics, recovery from propofol-induced anesthesia is generally quick and infrequently associated with such side effects as drowsiness, nausea, vomiting. Propofol may be used before diagnostic procedures requiring anesthesia, in the management of refractory status epilepticus, and for induction or maintenance of anesthesia before and during surgery. It may be administered as a bolus or an infusion, or as a combination of the two. First synthesized in 1973 by John B. Glen, a British veterinary anesthesiologist working for Imperial Chemical Industries (ICI, later AstraZeneca), propofol was introduced for therapeutic use as a lipid emulsion in the United Kingdom and New Zealand in 1986. Propofol (Diprivan) received FDA approval in October 1989. It is on the World Health Organization's List of Essential Medicines.
In May–June 1897, Thomson investigated whether or not the rays could be deflected by an electric field. Previous experimenters had failed to observe this, but Thomson believed their experiments were flawed because their tubes contained too much gas. Thomson constructed a Crookes tube with a better vacuum. At the start of the tube was the cathode from which the rays projected. The rays were sharpened to a beam by two metal slits – the first of these slits doubled as the anode, the second was connected to the earth. The beam then passed between two parallel aluminium plates, which produced an electric field between them when they were connected to a battery. The end of the tube was a large sphere where the beam would impact on the glass, created a glowing patch. Thomson pasted a scale to the surface of this sphere to measure the deflection of the beam. Any electron beam would collide with some residual gas atoms within the Crookes tube, thereby ionizing them and producing electrons and ions in the tube (space charge); in previous experiments this space charge electrically screened the externally applied electric field. However, in Thomson's Crookes tube the density of residual atoms was so low that the space charge from the electrons and ions was insufficient to electrically screen the externally applied electric field, which permitted Thomson to successfully observe electrical deflection.
== Contraindications == Pentoxyverine is contraindicated in persons with bronchial asthma or other kinds of respiratory insufficiency (breathing difficulties), as well as angle-closure glaucoma. No data are available for the use of pentoxyverine during pregnancy, lactation, or children under two years of age, wherefore the drug must not be used under these circumstances. Antitussive drugs are not useful in patients with extensive phlegm production because they prevent coughing up the phlegm.
== Legal status == Sweden's public health agency suggested classifying 4-fluorobutyrylfentanyl as hazardous substance on August 18, 2014. In October 2015, 4-fluorobutyrylfentanyl became a controlled substance in China. 4-Fluorobutyrfentanyl is a Schedule I controlled drug in the USA since 1. February 2018.
Sources: en.wikipedia.org
== Clinical trials == Sunobinop was generally well tolerated in 3 studies involving 70 healthy subjects at doses that ranged from 0.6 to 30 mg. The most prominent adverse event was dose-dependent sedation/somnolence, which was more common at doses greater than 10 mg. In these studies, most of the absorbed sunobinop was excreted unchanged via rapid renal elimination. The safety and effectiveness of sunobinop has not been evaluated by the FDA. There is no guarantee that sunobinop will successfully complete development or gain FDA approval.
== Mechanism of action == Gliotoxin is suspected to be an important virulence factor (aka pathogenicity factor) in Aspergillus fungus. Gliotoxin possesses immunosuppressive properties that may suppress and cause apoptosis in certain cells of the immune system, including neutrophils, eosinophils, granulocytes, macrophages, and thymocytes. Specifically, neutrophils exposed to gliotoxin release less reactive oxygen species (ROS) and complete fewer phagocytic activities. Gliotoxin is also believed to interfere with T-cell activation. Additionally, gliotoxin acts as an inhibitor of farnesyl transferase. It noncompetitively inhibits the chymotrypsin-like activity of the 20S proteasome. In vivo gliotoxin displays anti-inflammatory activity. It was investigated as an antibiotic and antifungal in the 1940s and as an antiviral agent. Gliotoxin inactivates many different enzymes, including nuclear factor-κB (NF-κB), NADPH oxidase, and glutaredoxin. The inhibition of NF-κB leads prevents cytokine release and induction of the inflammatory response. The immunosuppressive properties of gliotoxin are due to the disulfide bridge within its structure. Interactions occur between sulfur molecules that make up the disulfide bridge and thiol groups contained in cysteine residues. Gliotoxin acts by blocking thiol residues in the cell membrane. Gliotoxin also activates a member of the Bcl-2 family called Bak in order to mediate cell apoptosis. Activated Bak then causes the release of ROS, which form pores within the mitochondrial membrane.
=== Foreign === Order of the Most Holy Annunciation (Kingdom of Italy). Order of Saints Maurice and Lazarus (Kingdom of Italy). Order of the Crown of Italy (Kingdom of Italy). Order of Saint Januarius (Royal House of Bourbon-Two Sicilies) Sacred Military Constantinian Order of Saint George (Royal House of Bourbon-Two Sicilies) Imperial Order of Dom Pedro I (The Imperial House of Brazil) The Imperial Order of the Rose (The Imperial House of Brazil) Order of the Immaculate Conception of Vila Viçosa (Royal House of Braganza of Portugal) Bailiff’s Cross of the Order of Malta (Sovereign Military Order of Malta). National Order of the Legion of Honour in the rank of Commander (Republic of France). Jubilee medal on the occasion of the 50th birthday of HM King Carl XVI Gustaf, Kingdom of Sweden Jubilee medal on the occasion of the 70th birthday of HM King Carl XVI Gustaf, Kingdom of Sweden
Sources: en.wikipedia.org
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.
The fatty diacid side chain promotes strong binding to serum albumin, which slows clearance and yields a half-life of roughly five days. That profile supports once-weekly administration in clinical use.
In vitro assays detect activity at both the GIP and GLP-1 receptors, but the activity ratio depends on the assay system and the signalling pathway measured. The relative contribution of each receptor to clinical effects is still being characterised.
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.